Replies to post #34956 on Cel Sci Corporation (CVM)

[lightrock]

back of the napkin, first glance for that one...

first, take into consideration the market cap is already $1.9B

new cases of lupus per year seem to be up to 16,000

roll those forward there may be up to 300,000 people at risk of associated kidney disease

if I have read right so far, then the product ( which appears very positive ) probably has to play in that space of 300,000 total.

That would yield a dosage cost of $6,333 per patient to make the market cap in one year. Perhaps about $1,000 with a 6 or 7x multiple.

So the bottom line is that it is not easy to see if the "success" is already baked in to the share price. (at first glance)

I would guess it will pop but not that it will pop and hold.